## Karl Martin Wissing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5312412/publications.pdf

Version: 2024-02-01

117571 123376 3,944 104 34 61 citations h-index g-index papers 109 109 109 4613 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	3.8	524
2	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology Dialysis Transplantation, 2020, 35, 1973-1983.	0.4	312
3	Guidelines for the treatment and management of new-onset diabetes after transplantation1 Clinical Transplantation, 2005, 19, 291-298.	0.8	228
4	The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients. American Journal of Transplantation, 2011, 11, 1633-1644.	2.6	194
5	Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2009, 20, 1385-1392.	3.0	177
6	Cold Ischemia is a Major Determinant of Acute Rejection and Renal Graft Survival in the Modern Era of Immunosuppression. Transplantation, 2008, 85, S3-S9.	0.5	143
7	HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH INCREASED KIDNEY GRAFT LOSS CAUSED BY CHRONIC REJECTION IN MALE PATIENTS WITH PREVIOUS ACUTE REJECTION. Transplantation, 2000, 70, 464-472.	0.5	108
8	Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients 1. Transplantation, 2002, 74, 73-79.	0.5	100
9	A Controlled Study of Vitamin D3 to Prevent Bone Loss in Renal-Transplant Patients Receiving Low Doses of Steroids. Transplantation, 2005, 79, 108-115.	0.5	100
10	Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-up. American Journal of Kidney Diseases, 2008, 51, 471-477.	2.1	99
11	Primary vesicoureteral reflux detected in neonates with a history of fetal renal pelvis dilatation: A prospective clinical and imaging study. Journal of Pediatrics, 2006, 148, 222-227.	0.9	84
12	Regression of Left Ventricular Hypertrophy After Arteriovenous Fistula Closure in Renal Transplant Recipients: A Long-Term Follow-Up. American Journal of Transplantation, 2004, 4, 2038-2044.	2.6	81
13	Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients. American Journal of Transplantation, 2011, 11, 1444-1455.	2.6	75
14	Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2573-2578.	2.2	67
15	COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrology Dialysis Transplantation, 2021, 36, 2094-2105.	0.4	65
16	Conversion From Prograf to Advagraf Among Kidney Transplant Recipients Results in Sustained Decrease in Tacrolimus Exposure. Transplantation, 2011, 91, 566-569.	0.5	64
17	TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation. Journal of the American Society of Nephrology: JASN, 2009, 20, 2459-2467.	3.0	63
18	Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment. Transplantation Reviews, 2014, 28, 37-46.	1.2	59

#	Article	IF	CITATIONS
19	Current management of infants with fetal renal pelvis dilation: a survey by French-speaking pediatric nephrologists and urologists. Pediatric Nephrology, 2004, 19, 966-71.	0.9	58
20	Biochemical Parameters After Cholecalciferol Repletion in Hemodialysis: Results From the VitaDial Randomized Trial. American Journal of Kidney Diseases, 2014, 64, 696-705.	2.1	55
21	Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicology and Applied Pharmacology, 2013, 271, 276-284.	1.3	54
22	Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant International, 2007, 21, 071029080703003-???.	0.8	50
23	Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study. American Journal of Transplantation, 2015, 15, 1923-1932.	2.6	50
24	Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transplant Infectious Disease, 2011, 13, 397-406.	0.7	49
25	Major Histocompatibility Complex Class 1 Chain-Related Antigen A Antibodies: Sensitizing Events and Impact on Renal Graft Outcomes. Transplantation, 2010, 90, 168-174.	0.5	47
26	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation, 2018, 18, 1726-1734.	2.6	47
27	A PILOT TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-10 IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING OKT3 INDUCTION THERAPY1,2. Transplantation, 1997, 64, 999-1006.	0.5	46
28	Characteristics of First Urinary Tract Infection With Fever in Children. Pediatric Infectious Disease Journal, 2011, 30, 371-374.	1.1	43
29	Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. Clinical Microbiology and Infection, 2021, 27, 398-405.	2.8	43
30	HLA Mismatches Remain Risk Factors for Acute Kidney Allograft Rejection in Patients Receiving Quadruple Immunosuppression With Anti-Interleukin-2 Receptor Antibodies. Transplantation, 2008, 85, 411-416.	0.5	42
31	Genetic forms of nephrotic syndrome: a single-center experience in Brussels. Pediatric Nephrology, 2009, 24, 287-294.	0.9	38
32	Early prognostic factors of infants with chronic renal failure caused by renal dysplasia. Pediatric Nephrology, 2001, 16, 260-264.	0.9	36
33	Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications. Transplant International, 2007, 21, 071012050800003-???.	0.8	36
34	Arteriovenous fistula after renal transplantation: utility, futility or threat?. Nephrology Dialysis Transplantation, 2006, 21, 254-257.	0.4	35
35	Posttransplant Major Histocompatibility Complex Class I Chain-Related Gene A Antibodies and Long-Term Graft Outcomes in a Multicenter Cohort of 779 Kidney Transplant Recipients. Transplantation, 2012, 93, 1258-1264.	0.5	32
36	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.4	32

#	Article	IF	CITATIONS
37	Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2700-2705.	0.4	31
38	Effect of Atorvastatin Therapy and Conversion to Tacrolimus on Hypercholesterolemia and Endothelial Dysfunction After Renal Transplantation. Transplantation, 2006, 82, 771-778.	0.5	29
39	Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. BioMed Research International, 2018, 2018, 1-19.	0.9	29
40	Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatric Nephrology, 2018, 33, 2085-2093.	0.9	29
41	Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study. BMC Nephrology, 2014, 15, 104.	0.8	26
42	Conversion From Tacrolimus to Cyclosporin Is Associated With a Significant Improvement of Glucose Metabolism in Patients With New-Onset Diabetes Mellitus After Renal Transplantation. Transplantation Proceedings, 2005, 37, 1857-1860.	0.3	24
43	Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. Nephrology Dialysis Transplantation, 2012, 27, 2547-2553.	0.4	23
44	Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clinical Transplantation, 2005, 19, 475-482.	0.8	22
45	Arteriovenous Fistula Closure After Renal Transplantation: A Prospective Study With 24-Hour Ambulatory Blood Pressure Monitoring. Transplantation, 2008, 85, 482-485.	0.5	22
46	Ineligibility for renal transplantation: prevalence, causes and survival in a consecutive cohort of 445 patients. Clinical Transplantation, 2011, 25, 576-583.	0.8	21
47	Outcomes of kidney transplantations in children weighing 15 kilograms or less: a retrospective cohort study. Transplant International, 2018, 31, 720-728.	0.8	21
48	Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrology Dialysis Transplantation, 2008, 23, 3727-3729.	0.4	20
49	Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?. Pediatric Nephrology, 2018, 33, 395-408.	0.9	19
50	Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort. Nephrology Dialysis Transplantation, 2021, 36, 918-926.	0.4	16
51	The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation. International Immunology, 1995, 7, 1593-1598.	1.8	15
52	Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches. Transplantation Proceedings, 2000, 32, 3-5.	0.3	15
53	Thrombophilic Factors Do Not Predict Outcomes in Renal Transplant Recipients Under Prophylactic Acetylsalicylic Acid. American Journal of Transplantation, 2010, 10, 99-105.	2.6	14
54	Alkaline-encrusted pyelitis and cystitis: an easily missed and life-threatening urinary infection. BMJ Case Reports, 2011, 2011, bcr1220103613-bcr1220103613.	0.2	14

#	Article	IF	Citations
55	Accuracy of Automated Flow Cytometry-Based Leukocyte Counts To Rule Out Urinary Tract Infection in Febrile Children: a Prospective Cross-Sectional Study. Journal of Clinical Microbiology, 2016, 54, 2975-2981.	1.8	14
56	mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?. Nephrology Dialysis Transplantation, 2022, 37, 799-803.	0.4	13
57	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 1687-1698.	0.4	12
58	Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. CKJ: Clinical Kidney Journal, 2021, 14, 2463-2471.	1.4	12
59	Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantation. Clinical Nephrology, 2013, 79, 313-317.	0.4	12
60	Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 1566-1575.	0.4	12
61	Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EvoCit Study. American Journal of Kidney Diseases, 2022, 79, 79-87.e1.	2.1	11
62	DOWN-REGULATION OF INTERLEUKIN-2 AND INTERFERON-?? AND MAINTENANCE OF INTERLEUKIN-4 AND INTERLEUKIN-10 PRODUCTION AFTER ADMINISTRATION OF AN ANTI-CD3 MONOCLONAL ANTIBODY IN MICE1. Transplantation, 1999, 68, 677-684.	0.5	11
63	Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study. BMC Infectious Diseases, 2017, 17, 98.	1.3	10
64	Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation. Kidney International Reports, 2020, 5, 831-838.	0.4	10
65	In Search of an Efficient Complexing Agent for Oxalates and Phosphates: A Quantum Chemical Study. Nanomaterials, $2021, 11, 1763$ .	1.9	8
66	Recurrent <i>Scedosporium apiospermum</i> skin infection in a renal transplant recipient. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 95-96.	1.3	7
67	Shipping donor kidneys within Eurotransplant: outcomes after renal transplantation in a single-centre cohort study. Nephrology Dialysis Transplantation, 2012, 27, 3638-3644.	0.4	7
68	Urokinase-Containing Locking Solution in the Prevention of Dialysis Catheter Dysfunction: A Double Blind Randomized Controlled Trial. Journal of Vascular Access, 2017, 18, 436-442.	0.5	7
69	Acid-base and electrolyte disturbances in patients with diabetes mellitus. Acta Clinica Belgica, 2019, 74, 28-33.	0.5	7
70	Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA. Nephrology Dialysis Transplantation, 2022, 37, 1140-1151.	0.4	7
71	Induction protocols: yesterday, today, and tomorrow. Transplantation Proceedings, 1999, 31, 1100-1101.	0.3	6
72	Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure. CKJ: Clinical Kidney Journal, 2016, 9, 319-323.	1.4	6

#	Article	IF	Citations
73	Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time?. Nephrology Dialysis Transplantation, 2017, 32, 745-747.	0.4	5
74	Variability in the incidence of renal replacement therapy over time in Western industrialized countries: A retrospective registry analysis. PLoS ONE, 2020, 15, e0235004.	1.1	5
75	Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study. Journal of Vascular Access, 2019, 20, 60-69.	0.5	4
76	Encrusted Uropathy: A Comprehensive Overviewâ€"To the Bottom of the Crust. Frontiers in Medicine, 2020, 7, 609024.	1.2	4
77	Randall's plaque as the origin of idiopathic calcium oxalate stone formation: an update. Comptes Rendus Chimie, 2022, 25, 373-391.	0.2	4
78	Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis. Respiration, 2012, 84, 70-74.	1.2	3
79	Prospective Cohort Study Investigating the Safety and Efficacy of Ambulatory Treatment With Oral Cefuroxime-Axetil in Febrile Children With Urinary Tract Infection. Frontiers in Pediatrics, 2018, 6, 237.	0.9	3
80	Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial. PLoS ONE, 2021, 16, e0251793.	1.1	3
81	Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis. Nephrology Dialysis Transplantation, 2021, 36, 2308-2320.	0.4	3
82	SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies. Transplant Immunology, 2022, 74, 101670.	0.6	3
83	Susceptibility and resistance to autoimmunity following neonatal injection of semi-allogeneic spleen cells in rats. Journal of Autoimmunity, 1992, 5, 629-640.	3.0	2
84	A preventable cause of transplant hydroureteronephrosis: inguinal herniation of the transplant ureter: case report and review of the literature. Acta Chirurgica Belgica, 2019, 121, 1-6.	0.2	2
85	Laparoscopic-Assisted Recipient Nephrectomy and Recipient Kidney Procurement during Orthotopic Living-Related Kidney Transplantation. Case Reports in Transplantation, 2011, 2011, 1-4.	0.1	1
86	Balancing Immunosuppressive Efficacy and Prevention of Posttransplant Diabetes—A Question of Timing and Patient Selection. Kidney International Reports, 2018, 3, 1249-1252.	0.4	1
87	5‥ear outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients. Transplant International, 2021, 34, 313-326.	0.8	1
88	MODULATION OF THE RELEASE OF CYTOKINES AND REDUCTION OF THE SHOCK SYNDROME INDUCED BY ANTI-CD3 MONOCLONAL ANTIBODY IN MICE BY INTERLEUKIN-10. Transplantation, 1994, 57, 1436-1439.	0.5	1
89	Did the Release of KDOQI Guidelines Really Improve the Control of Bone Mineral Metabolism in Hemodialysis Patients?. American Journal of Kidney Diseases, 2007, 50, 686.	2.1	0
90	Pulmonary Limited MPO-ANCA Microscopic Polyangiitis and Idiopathic Lung Fibrosis in a Patient with a Diagnosis of IgA Nephropathy. Case Reports in Nephrology, 2015, 2015, 1-5.	0.2	0

#	Article	IF	CITATIONS
91	MP109MEDICAL AND DIETARY MEASURES FOR THE PREVENTION OF NEPHROLITHIASIS: A SINGLE CENTER EXPERIENCE. Nephrology Dialysis Transplantation, 2016, 31, i378-i378.	0.4	0
92	SO061OUTCOMES OF KIDNEY TRANSPLANTATION IN CHILDREN WEIGHING â‰ <b>4</b> 5 KG. Nephrology Dialysis Transplantation, 2016, 31, i25-i25.	0.4	0
93	MO033EVOLUTION OF RENAL FUNCTION IN A LARGE COHORT OF HIV POSITIVE PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: A RETROSPECTIVE COHORT STUDY. Nephrology Dialysis Transplantation, 2016, 31, i41-i41.	0.4	O
94	SPOO2HYPONATREMIA IS A MARKER OF SEVERITY OF HIV DISEASE IN COMBINED ANTIRETROVIRAL THERAPY-NAIVE PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT STUDY. Nephrology Dialysis Transplantation, 2016, 31, i86-i87.	0.4	0
95	SP415EFFICACY OF THROMBOLYSIS WITH UROKINASECONTAINING LOCKING SOLUTIONS FOR THROMBOTIC DYSFUNCTION OF TUNNELLEDHEMODIALYSIS CATHETERS: A RETROSPECTIVE SINGLE-CENTRE COHORT STUDY. Nephrology Dialysis Transplantation, 2016, 31, i229-i230.	0.4	О
96	SP429CITRATE-BASED LOCKINGSOLUTIONS ARE MORE EFFICIENT THAN TAUROLIDINE-BASED LOCKING SOLUTIONS TOPREVENT THROMBOTIC DYSFUNCTION OF TUNNELLED HEMODIALYSIS CATHETERS: ARETROSPECTIVE COHORT STUDY. Nephrology Dialysis Transplantation, 2016, 31, i234-i234.	0.4	0
97	SP716AUTOMATED FLOW CYTOMETRY OF URINARY WHITE BLOOD CELLS IS A HIGHLY SENSITIVE SCREENING TEST FOR URINARY TRACT INFECTION IN CHILDREN: A CROSS-SECTIONAL STUDY. Nephrology Dialysis Transplantation, 2016, 31, i335-i335.	0.4	0
98	SuO006PREVENTION OF TUNNELED CUFFED CATHETER DYSFUNCTION WITH PROPHYLACTIC USE OF TAUROLIDINE LOCKING SOLUTION CONTAINING UROKINASE: A PROSPECTIVE AND RANDOMIZED PLACEBO-CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i619-i619.	0.4	0
99	FO045ABSENCE OF MEASURABLE CONTACT SYSTEM ACTIVATION OF COAGULATION DURING HAEMODIALYSIS: A RANDOMIZED CROSSOVER STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
100	Improving outcomes after renal transplantation starts well before surgery – the role of renal replacement modality. Transplant International, 2020, 33, 373-375.	0.8	0
101	P1054COMBINING A HEPARIN-GRAFTED DIALYZER WITH A CITRATE ENRICHED DIALYSATE OFFERS ADEQUATE HEMODIALYSIS EFFICACY AVOIDING SYSTEMIC ANTICOAGULATION: RESULTS OF THE NON-INFERIORITY RANDOMIZED EVOCIT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	О
102	P1630IS THERE ALWAYS A SURVIVAL BENEFIT WITH KIDNEY TRANSPLANTATION? RESULTS FROM A BELGIAN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
103	MO021ENHANCED MCP-1 RELEASE IN EARLY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
104	SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?. Journal of the American Society of Nephrology: JASN, 2022, 33, 869-870.	3.0	0